Table 7. Rates of complete response (CR)... | American Society of Hematology

Table 7.

Rates of complete response (CR) and overall survival (OS) among 128 patients with diffuse large B-cell lymphoma, according to the main prognostic factors

	n^7-150	CR rate, %	5-year OS, %	P
Age, y				.004
Younger than 60	45	69	60
60 years or older	84	52	34
B symptoms				.05
No	77	64	50
Yes	50	47	34
Performance status				.00001
ECOG 0,1	67	72	62
ECOG 2-4	58	40	22
Ann Arbor stage				.00002
I/II	62	73	62
III/IV	65	41	25
Bulky disease				.001
No	91	65	53
Yes	34	39	23
Extranodal involvement
2 or fewer sites	98	61	49	.004
More than 2 sites	30	43	23
Bone marrow				.016
Negative	102	62	49
Positive	22	35	19
Serum LDH				.007
Normal	52	72	54
High	63	47	36
IPI				< .00001
Low risk	37	83	82
Low/intermediate risk	26	65	36
High/intermediate risk	22	55	32
High risk	33	26	16
Bcl-2 expression				.03
Negative (25% or less)	52	62	57
Positive (more than 25%)	74	54	34
Differentiation pattern				NS
GC-CD10⁺	24	50	40
GC-CD10⁻	30	69	54
pGC	60	55	42

	n^7-150	CR rate, %	5-year OS, %	P
Age, y				.004
Younger than 60	45	69	60
60 years or older	84	52	34
B symptoms				.05
No	77	64	50
Yes	50	47	34
Performance status				.00001
ECOG 0,1	67	72	62
ECOG 2-4	58	40	22
Ann Arbor stage				.00002
I/II	62	73	62
III/IV	65	41	25
Bulky disease				.001
No	91	65	53
Yes	34	39	23
Extranodal involvement
2 or fewer sites	98	61	49	.004
More than 2 sites	30	43	23
Bone marrow				.016
Negative	102	62	49
Positive	22	35	19
Serum LDH				.007
Normal	52	72	54
High	63	47	36
IPI				< .00001
Low risk	37	83	82
Low/intermediate risk	26	65	36
High/intermediate risk	22	55	32
High risk	33	26	16
Bcl-2 expression				.03
Negative (25% or less)	52	62	57
Positive (more than 25%)	74	54	34
Differentiation pattern				NS
GC-CD10⁺	24	50	40
GC-CD10⁻	30	69	54
pGC	60	55	42

NS indicates not significant.

F7-150

The n shown is the number of patients for whom data were available.

View Large

This Feature Is Available To Subscribers Only